Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.98 +1.1%	$0.99	$0.91 ▼ $2.20	$29.19M	0.88	54,588 shs	18,122 shs
INKT MiNK Therapeutics	$28.01 -31.0%	$9.52	$4.56 ▼ $76.00	$161.86M	0.19	229,445 shs	1.47 million shs
KA Kineta		$0.66	$0.33 ▼ $5.39	$7.04M	0.46	409,478 shs	530,700 shs
SCYX SCYNEXIS	$0.76 -7.2%	$0.81	$0.66 ▼ $2.29	$31.96M	1.57	165,593 shs	305,395 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	+1.05%	+5.06%	+4.28%	-20.95%	-30.97%
INKT MiNK Therapeutics	-31.03%	+289.03%	+283.17%	+257.73%	+145.70%
KA Kineta	0.00%	0.00%	0.00%	0.00%	-20.21%
SCYX SCYNEXIS	-7.20%	+6.98%	-5.88%	-16.72%	-65.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYAI Dyadic International	3.1666 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.0
INKT MiNK Therapeutics	1.1101 of 5 stars	1.3	3.0	0.0	0.0	2.9	1.7	0.6
KA Kineta	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	1.0793 of 5 stars	0.0	3.0	0.0	0.0	3.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	3.00	Buy	$6.00	512.12% Upside
INKT MiNK Therapeutics	2.33	Hold	$37.50	33.88% Upside
KA Kineta	0.00	N/A	N/A	N/A
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KA, INKT, SCYX, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.49M	8.45	N/A	N/A	$0.08 per share	12.25
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($4.94) per share	N/A
KA Kineta	$5.44M	0.00	N/A	N/A	$0.29 per share	0.00
SCYX SCYNEXIS	$3.75M	7.91	N/A	N/A	$1.45 per share	0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$5.81M	-$0.20	N/A	N/A	N/A	-163.94%	-233.69%	-59.37%	8/12/2025 (Estimated)
INKT MiNK Therapeutics	-$9.51M	-$2.52	N/A	N/A	N/A	N/A	N/A	-140.72%	8/12/2025 (Estimated)
KA Kineta	-$14.10M	-$1.50	N/A	N/A	N/A	N/A	-1,044.95%	-336.46%	N/A
SCYX SCYNEXIS	-$21.29M	-$0.56	N/A	15.20	N/A	-1,030.04%	-53.47%	-32.86%	8/6/2025 (Estimated)

Latest KA, INKT, SCYX, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DYAI Dyadic International	-$0.06	N/A	N/A	N/A	$0.60 million	N/A
8/12/2025	Q2 2025	INKT MiNK Therapeutics	-$0.45	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	INKT MiNK Therapeutics	-$0.61	-$0.70	-$0.09	-$0.70	N/A	N/A
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/14/2025	Q1 2025	DYAI Dyadic International	N/A	-$0.07	N/A	-$0.07	N/A	$0.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
KA Kineta	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	5.40	3.98	3.98
INKT MiNK Therapeutics	N/A	0.30	0.30
KA Kineta	0.05	0.14	0.14
SCYX SCYNEXIS	N/A	5.83	5.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
INKT MiNK Therapeutics	2.87%
KA Kineta	30.32%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	29.50%
INKT MiNK Therapeutics	22.48%
KA Kineta	23.70%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	7	30.09 million	21.21 million	Optionable
INKT MiNK Therapeutics	30	3.99 million	3.09 million	No Data
KA Kineta	40	12.25 million	9.35 million	Not Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable

KA, INKT, SCYX, and DYAI Headlines

Recent News About These Companies

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

October 10, 2024 | globenewswire.com

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

October 7, 2024 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

October 3, 2024 | globenewswire.com

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 Shares

September 17, 2024 | insidertrades.com

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

August 27, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KA, INKT, SCYX, and DYAI Company Descriptions

Dyadic International NASDAQ:DYAI

$0.98 +0.01 (+1.05%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.99 +0.01 (+0.69%)

As of 07/15/2025 06:59 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

MiNK Therapeutics NASDAQ:INKT

$28.01 -12.60 (-31.03%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$26.59 -1.42 (-5.08%)

As of 07:28 AM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Kineta NASDAQ:KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

SCYNEXIS NASDAQ:SCYX

$0.76 -0.06 (-7.20%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.00 (+0.39%)

As of 07/15/2025 05:03 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time